We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
REXULTI (Lundbeck Australia Pty Ltd)
Product name
REXULTI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 (255 working days)
Active ingredients
brexpiprazole
Registration type
EOI
Indication
Treatment of agitation associated with Alzheimer’s dementia (AAD), in patients who are unresponsive to non-pharmacological interventions.